On October 2, 2024 Volastra Therapeutics, a clinical-stage biotechnology company, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally discovered KIF18A inhibitor (Press release, Volastra Therapeutics, OCT 2, 2024, View Source [SID1234647004]). The designation has been granted for the treatment of patients with platinum-resistant high-grade serous ovarian cancer (HGSOC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Platinum-resistant high-grade serous ovarian cancer is marked by poor prognosis, highlighting the urgent need for new therapies for this devastating disease," said Scott Drutman, M.D., Ph.D., Head of Research & Development and Chief Medical Officer. "Fast Track designation for VLS-1488 reaffirms the clear potential of KIF18A inhibition to address this unmet medical need and represents a critical step towards bringing these novel therapeutics to patients. We look forward to working closely with the FDA as we advance the development of inhibitors against this promising target."
Fast Track designation is a program intended to facilitate and expedite the development and review of new drugs for the treatment of a serious or life-threatening condition. To qualify for this designation, there must be clear data demonstrating the drug has potential to address unmet medical need in the designated condition.
In the U.S. alone, there are more than 20,000 new cases of ovarian cancer each year, over 75% of which are advanced. Most of these patients will see disease progression on platinum-based chemotherapy. Sovilnesib, the second of Volastra’s two KIF18A inhibitors, which was in-licensed from Amgen in 2023, has previously been granted Fast Track designation in this indication. Each of Volastra’s two KIF18A inhibitors, VLS-1488 and sovilnesib, has unique profiles and are both enrolling patients in early-phase studies.
The Phase I/II trial for VLS-1488 is evaluating safety, tolerability and preliminary efficacy in patients with advanced tumors, including HGSOC. Further details of the trial can be found at www.clinicaltrials.gov under NCT identifier: NCT05902988.